1. Part 1

2. Microemulsions Definition &Composition:
Self emulsifying drug delivery systems (SEDDS) described as homogeneous mixtures of natural or synthetic solid or liquid surfactants and cosurfactants.
Also “Microemulsions” might defined as are liquid dispersions of water and oil that are made homogenous, transparent (or translucent) and thermodynamically stable by the addition of relatively large amounts of a surfactant and a co-surfactant and having diameter of the droplets in the range
of 100 – 1000 A (10 – 100 nm).
Compare: ME, Emulsions and Micellar systems. (see figure)
Physicochemical properties of ME:
Thermodynamic stability,
They form transparent or transluscent dispersions,
Self emulsifying properties,
They have excellent solubilisation capacity.
Droplet size (mostly)<100 nm,
They form O/W or O/W or bi-continuous systems. (see figure)

3. Figure. Structures of Micellar solution, Microemulsion and Emulsion

5. Energy Change of ME formation:
For o/w dispersion of liquid paraffin, γo/w=55 mJ.m-2, ∆G= γ ∆ A* calculated at different droplet sizes,
d=1 cm = 0.01 m
∆G = 55 mJ.m-2 * (3.1416*[0.01]2 m2)
= mJ,
d= 10 um >> (1cm)3/(10 um)3 =V1/V2
1 cm globule >>109 globules,
∆G = 109{55 mJ.m-2 * *[0.05]2 m2)
= mJ
d= 1um (1000 nm) ∆G = mJ
Sphere area = pi*sq. diameter = 4*pi*sq. radius

6. Role of Cosurfactant:
ME droplet (about 100nm)
>> huge interfacial area,
But ME are thermodynamically stable. HOW?
γo/w cyclohexane/water)=42 mJ. m-2
Add 10-4g/ml SDS>> γo/w = 2 mJ. m-2
Add 20% pentanol>> γo/w = 10 mJ. m-2
Add of both >> very low γo/w value
>> spontaneous ME formation.

8. Ternary phase diagrams in ME formulation

9. Part 2

10. Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo International Journal of Pharmaceutics 286 (2004) 147–156
Background:
Systemic Paclitaxel has anti-tumor activity.
Paclitaxel is available only as injected solution (Taxol®).
Taxol® > paclitaxel in Cremophor EL and alcohol (1:1).
Cremophor EL: has severe side effects on humans,
Paclitaxel injection: patient’s incompliance by daily injection.
Other delivery systems (liposome, nanosphere and parenteral emulsions) were investigated.
Each system has its own disadvantages.

11. Emulsion may be a promising alternative way because:
it provides good biocompatibility,
longer shelf life,
good solubilization of poorly water soluble drugs, and
high concentration of lipophilic drugs in aqueous media ( if controlled release)
BUT the rapid drug release made emulsion not proper to deliver anti-cancer drugs parenterally.
Self-microemulsifying drug delivery systems (SMEDDS) are one of the suggested alternatives.
SMEDDS are isotropic mixtures of oil, a surfactant, and possibly one or more hydrophilic solvents or cosurfactants, which form fine oil-in-water emulsions or microemulsions when exposed to aqueous media under condition of gentle agitation.
biodegradable polymer (PLGA) is included to control the release.
Research Aim:
To develop the optimal formulation of SMEDDS containing paclitaxel and PLGA for the improvement of release characteristics without any property change, such as chemical property of paclitaxel and weight loss of PLGA.

12. Techniques include:
GPC: Mol.Wt analysis of solubilzed PLGA.
DLS: ME droplet size analysis
TEM and AFM: ME droplet Morphology.
In vitro release.
In vitro anti-tumor activity test.
In vivo anti-tumor activity test.

13. ME Components:
Drug: Paclitaxel
Labrafill M-1944CS:Polyglycolyzed glycerides. Oily phase for ME and selfemulsifying liquids. HLB= 4 [cosurfactant]
Cremophor ELP: polyoxyl 35 castor oil. Solubilizer and stabilizer for emulsions. HLB= [surfactant]
Tetraglycol: Tetraethylene glycol. Solvent used in I.V and I.M injections [solubilizer]
PLGA: molecular weights of 8K,33K, and 90K [polymer]

14. Phase diagram study:
water titration method,
Try different surfactant/cosurfactant ratios: 0.5:1, 1:1, 1.5:1, and 2:1 (w/w)
Solubilizer+drug+PLGA > transparent and homogenous mixture
Above mixture > titrate with water,
>visually observed for phase clarity and flow ability > ME formation.
After the identification of ME region in the phase diagrams, the ME formulations were selected at desired component ratios.

15. Preparation of Samples
A series of SMEDDS was prepared with various PLGA and/or paclitaxel, solubilizer, surfactant, and cosurfactant.
PLGA and/or paclitaxel > dissolved by tetraglycol in glass vials.
Surfactant and cosurfactant were accurately
weighed into the glass vials.
The components were mixed by gentle stirring and vortex mixing until paclitaxel had perfectly dissolved.
The mixture was stored at room temperature until used.
Before using, ME was formed from SMEDDS with contacting aqueous phase.

16. Results and Discussion
Phase behavior (read from article)
Pseudoternary phase diagrams were constructed to identify the self-emulsifying regions and to optimize the concentration of surfactant and cosurfactant.
> The efficiency of emulsification was good when the S/CoS
concentration was more than 40% of SMEDDS formulation.
> S/CoS ratio 1:1 ratio was the most stable after formation of microemulsion and has the broadest self-emulsifying regions with using small amount of surfactant (which is required in paclitaxel bio application).

17. Fig. 1. Pseudo-ternary phase diagrams indicating the efficient self-emulsification region (S/CoS: (a) 0.5:1; (b) 1:1, the dot area represents O/W microemulsion existence range).

18. Molecular weight analysis by GPC:
Generally, molecular weight of PLGA is an important role to control the release profile of drug as a matrix.
Therefore, change of molecular weight of PLGA solubilized in SMEDDS has to be checked before and after solubilization.
> There was no change in molecular weight of PLGA after being solubilized by
tetraglycol.

19. Droplet size analysis and morphology
The droplet size for all formulations was found in the
range of 45–195 nm.
The formulation of microemulsion could affect droplet size by following factors such as including PLGA, the molecular weight of PLGA, and type of cosurfactant and surfactant. It could suggest that this is the most optimal formulation
The morphology of microemulsion showed the spherical shape and uniform droplet size of microemulsion.
It was also observed that the droplet size of microemulsion prepared without PLGA was smaller than that of
microemulsion containing PLGA.
It could be suggested that the presence of PLGA in microemulsion affected the droplet size when
the same formulation was used.

20. Drug Release: Release profiles of paclitaxel from a paclitaxel microemulsion prepared by formulation A; B; C; D, respectively (n = 5). Each value represents the mean±S.D.

21. Cytotoxicity of paclitaxel from a paclitaxel microemulsion containing PLGA against human breast cancer cell line MCF7 in vitro.

22. Antitumor effect: Tumor volume changes of animals treated with saline paclitaxel-free microemulsion prepared by formulation B, paclitaxel microemulsion prepared by formulation A; B , respectively

23. CONCLUSION
The release behaviour of paclitaxel from ME containing PLGA having various molecular weights exhibited sustained release in contrast that the release of paclitaxel from ME without PLGA was very rapid.
ME containing PLGA enhances its anti-tumor activity as compared to ME without PLGA.
These results strongly prove that the formulations developed in this study could be used for clinical trials.

24. Part 3

25. A new microemulsion formulation of Cyclosporine
Microemulsion- A suitable Galenical approach for the absorption enhancement of low soluble compounds B.T. Gattefosse No. 88, p , 1995
A new microemulsion formulation of Cyclosporine

26. Objective: Cyclosporine A (CsA) absorption enhancement
using ME formulation.
CsA: immunosuppressive agent. Used for patient after
organ transplantation. Used also in the treatment of
autoimmune disorders.
Among the CsA available dosage forms:
Injections: have severe side effects.
The oral route is good alternative (emulsion and microemulsion);
CsA classical Sandimmune® emulsion:
In the aqueous G.I.T, it forms crude emulsion
good oral bioavailability, but with many disadvantages.
CsA Sandimmune® Neoral ® microemulsion:
In the aqueous G.I.T, it forms microemulsion, with many advantages.

27. Why CsA needs absorption enhancement
Why CsA needs absorption enhancement? large polypeptide, Mwt=1202 dalton, highly lipophilic, water solubility<0.002%.

28. What are the disadvantages of CsA classical Sandimmune® (capsule) macroemulsion dosage form?
1. Bile salt emulsification>digestion by pancreatic juice> CsA absorption,
2. CsA distributed into 3 phases:
>ppted. Ca soap (small amount of CsA)
>undigested lipid (large amount of CsA)
>mixed micellar (small amount of CsA)
(see figure)
3. Narrow absorption widow > more reduction in Sandimmune® bioavailability. (See figure)
4. Inter and intra individual variations (digestion dependant, pH, food, physiological factors).

29. Median absorption of Cs after intradoudenal administration of Sandimmune® pre-digested phases to bile duct cannulated rats (n=6).

30. Median relative bioavailability of 150 mg Cs after administration by intubation to different sites of the G.I.T in healthy volunteers (n=10).

31. Requirements of the ideal CsA formula:
Fast release (use of the entire window),
mimicking the mixed micellar phase,
Stable, not affected by physiological conditions
>>> microemulsion pre-concentrate with the right type and level of excipients was developed (Sandimmune® Neoral ® ).
Composition of Neoral ® SMEDDS formulation:

32. Composition of formulation
Neoral ® SMEDDS
Oil: hydrolyzed corn oil,
Surfactant: polyoxy-hydrogenated castor oil
Solvent: glycerol, ethanol or PG
Drug content:10%
Tocopherol: as antioxidant
Neoral ® SMEDDS administered in soft or hard gelatin capsule, the digestive motility in the G.I.T provides the agitation necessary for self-emulsification. ME will form in situ with average droplet size as low as 30 nm.

33. Sandimmune® Neoral ®
Against
Sandimmune®

34. Formation of homogenous transparent ME, stable upon dilution with water (right). Left: Cs suspension, mid: Sandimmune®

35. Production of constant, narrow range droplet size

36. Reduction of inter and intra individual variability.

37. Reduction of the food interaction. Fasting and fat-rich meal.

38. Reduction of the impact of bile on Cs absorption
Reduction of the impact of bile on Cs absorption. A: Sandimmune® Neoral ® , B: Sandimmune®

39. Improved bioavailability and dose linearity.